SONOSCAPE(SZ:300633) Sou Hu Cai Jing·2026-01-19 12:18Core Viewpoint - The stock of Kaili Medical (300633) has shown a decline in price and significant changes in financial performance, indicating potential investment considerations and market reactions [1][2]. Financial Performance - For the first three quarters of 2025, Kaili Medical reported a main revenue of 1.459 billion yuan, an increase of 4.37% year-on-year [2]. - The net profit attributable to shareholders was 33.51 million yuan, a decrease of 69.25% year-on-year [2]. - The net profit after deducting non-recurring items was 23.99 million yuan, down 72.14% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 495 million yuan, up 28.42% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -13.52 million yuan, an increase of 78.05% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -15.89 million yuan, an increase of 76.92% year-on-year [2]. - The company's debt ratio stands at 24.22%, with investment income of 2.08 million yuan and financial expenses of -38.30 million yuan [2]. - The gross profit margin is reported at 60.36% [2]. Market Activity - As of January 19, 2026, the stock closed at 28.5 yuan, down 1.08%, with a turnover rate of 0.8% [1]. - The trading volume was 34,400 hands, with a total transaction amount of 99.12 million yuan [1]. - On January 19, the net outflow of main funds was 5.936 million yuan, accounting for 5.99% of the total transaction amount [1]. - Retail investors saw a net inflow of 4.33 million yuan, representing 4.37% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, 10 institutions have provided ratings for Kaili Medical, with 8 buy ratings and 2 hold ratings [2]. - The average target price set by institutions over the past 90 days is 3.971 billion yuan [2].